[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340182-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340182-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeted-therapy-of-cancer-stem-cells-inhibition-of-mtor-in-pre-clinical-and-clinical-research","Targeted therapy of cancer stem cells - inhibition of mTOR in pre-clinical and clinical research","","Cancer stem cells (CSCs) combine stem-like self-renewal and proliferation with cancer cell properties, contributing to tumor origin and recurrence. The review focuses on the mTOR pathway as a central signaling hub linked to PI3K/AKT and MAPK cascades, regulating both CSC generation and pluripotency maintenance. By targeting CSCs through mTOR inhibition, mTOR-based strategies are framed as increasingly important for overcoming limitations such as drug resistance, while highlighting the need for careful clinical design due to mTOR roles in normal cellular functions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeted-therapy-of-cancer-stem-cells-inhibition-of-mtor-in-pre-clinical-and-clinical-research/340182/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeted-therapy-of-cancer-stem-cells-inhibition-of-mtor-in-pre-clinical-and-clinical-research/340182.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are cancer stem cells (CSCs) important targets in cancer treatment?","Question",{"text":63,"@type":64},"CSCs possess stem-like self-renewal and strong proliferation, and they can differentiate into tumor cell types. Their stem-like cancer properties make them central to tumor development and treatment challenges.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the mTOR pathway relate to CSC biology?",{"text":68,"@type":64},"The review describes mTOR as a key signaling pathway connected to PI3K/AKT and MAPK cascades. It influences CSC generation and the maintenance of pluripotency, with regulation of mTOR signaling shaping differentiation.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the main concerns when using mTOR inhibition in therapy?",{"text":72,"@type":64},"Although mTOR inhibitors show promise in suppressing CSC differentiation and reducing metastasis, the review emphasizes caution because mTOR is involved in normal cellular activities. This requires strategies to minimize potential side effects and improve targeted delivery.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340182,1790160490,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","[www.nature.com/cddis](www.nature.com/cddis)  \nREVIEW ARTICLE OPEN   \nTargeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research  \nBoram Son1,2,5, Wonhwa Lee 3,5, Hyeonjeong Kim1, Heungsoo Shin 1 ✉ and Hee Ho Park 1,4 ✉  \n© The Author(s) 2024  \n|  |  |  |\n| --- | --- | --- |\n|  | Cancer stem cells (CSCs) are a type of stem cell that possesses not only the intrinsic abilities of stem cells but also the properties of cancer cells. Therefore, CSCs are known to have self-renewal and outstanding proliferation capacity, along with the potential to differentiate into speciﬁc types of tumor cells. Cancers typically originate from CSCs, making them a signiﬁcant target for tumor treatment. Among the related cascades of the CSCs, mammalian target of rapamycin (mTOR) pathway is regarded as one of the most important signaling pathways because of its association with signiﬁcant upstream signaling: phosphatidylinositol 3‑kinase/ protein kinase B (PI3K/AKT) pathway and mitogen‑activated protein kinase (MAPK) cascade, which inﬂuence various activities of stem cells, including CSCs. Recent studies have shown that the mTOR pathway not only affects generation of CSCs but also the maintenance of their pluripotency. Furthermore, the maintenance of pluripotency or differentiation into speciﬁc types of cancer cells depends on the regulation of the mTOR signal in CSCs. Consequently, the clinical potential and importance of mTOR ineffective cancer therapy are increasing. In this review, we demonstrate the association between the mTOR pathway and cancer, including CSCs. Additionally, we discuss a new concept for anti-cancer drug development aimed at overcoming existing drawbacks, |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| such as drug resistance, by targeting CSCs through mTOR inhibition. |  |  |\n|  | Cell Death and Disease (2024)15:696; [https://doi.org/10.1038/s41419-024-07077-8](https://doi.org/10.1038/s41419-024-07077-8) |  |\n|  |  |  |\n\nFACTS  \n● Cancer treatment faces challenges due to its complexity, with chemotherapy limited by drug resistance, prompting the exploration of advanced therapeutic approaches.  \n● Cancer Stem Cells (CSCs) are a key focus, sharing characteristics with normal stem cells and being targeted to prevent differentiation into tumor cells and promote self-renewal.  \n● The mTOR pathway plays a pivotal role in activating stem and immune cells within cancer tissues, leading to the development and utilization of mTOR inhibitors in FDA-approved cancer treatments.  \n● Clinical trials categorize mTOR inhibitors for various cancer types, demonstrating their efﬁcacy in suppressing CSC differentiation, intrinsic stem cell properties, and reducing metastasis.  \n● Despite promising results, caution is warranted in mTOR inhibition due to its involvement in normal cellular activities, necessitating careful strategies to avoid potential side effects and the development of advanced, targeted tumor therapies.  \nOPEN QUESTIONS  \n● How can CSC-targeting therapy effectively prevent tumor recurrence, considering the pivotal role of CSCs in tumor  \nrelapse, metastasis, and resistance to radiotherapy and chemotherapy?  \n● What intrinsic factors contribute to the development of resistance in CSCs, including their longer cell cycle, DNA repair system, and involvement of oxidative modulators and metabolic plasticity regulators?  \n● In what ways does the PI3K/AKT/mTOR axis contribute to CSC resistance, and what are the outcomes and implications of clinical trials involving mTOR pathway inhibitors for various cancers?  \n● What challenges are associated with delivering anti-cancer drugs to CSCs, and how effective are viral delivery systems like adenovirus and nanoparticle therapeutics in reaching and targeting CSCs, considering existing challenges in these delivery methods?  \nINTRODUCTION  \nStem cells are known for their three unique ","cbCaijq0oLBrcM7s","https://ap.wps.com/l/cbCaijq0oLBrcM7s","pdf",3932643,18,"English","# FACTS\n# OPEN QUESTIONS\n# INTRODUCTION","[{\"question\":\"Why are cancer stem cells (CSCs) important targets in cancer treatment?\",\"answer\":\"CSCs possess stem-like self-renewal and strong proliferation, and they can differentiate into tumor cell types. Their stem-like cancer properties make them central to tumor development and treatment challenges.\"},{\"question\":\"How does the mTOR pathway relate to CSC biology?\",\"answer\":\"The review describes mTOR as a key signaling pathway connected to PI3K/AKT and MAPK cascades. It influences CSC generation and the maintenance of pluripotency, with regulation of mTOR signaling shaping differentiation.\"},{\"question\":\"What are the main concerns when using mTOR inhibition in therapy?\",\"answer\":\"Although mTOR inhibitors show promise in suppressing CSC differentiation and reducing metastasis, the review emphasizes caution because mTOR is involved in normal cellular activities. This requires strategies to minimize potential side effects and improve targeted delivery.\"}]","Targeted therapy of cancer stem cells - inhibition of mTOR in pre-clinical and clinical research | PDF",1790034719,45,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b9365e10ec6b729f360783122ea5e728.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d58cb33419f1d1c5c222446ee798a28f.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aeb478923ebc1541b3829d81e5832b73.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37e17cc285d1afb82567f93b898e4145.webp",980,1301]